Novartis Sues Teva Over Premature ANDA Letters

Law360, New York (July 28, 2008, 12:00 AM EDT) -- Teva Pharmaceuticals Industries Ltd. jumped the gun in notifying Novartis Corp. that it planned to make generic versions of the Swiss drugmaker's bone treatment Zometa, according to a lawsuit filed Thursday in federal court.

Novartis filed the suit in the U.S. District Court for the District of Delaware accusing Teva of sending Paragraph IV certifications for the proposed generic without first filing abbreviated new drug applications with the U.S. Food and Drug Administration.

The suit claims that Teva's actions started the clock early on the patent...
To view the full article, register now.